Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine

Sleep

Volumn 26, Issue 5, 2003, Pages 602-606

  Markowitz, Jeffrey S ^a   Gutterman, Elane M ^a   Lilienfeld, Sean ^b   Papadopoulos, George ^c  

^a Health Data Analytics   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer disease; Galantamine; Sleep quality

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDICAL RECORD; MINI MENTAL STATE EXAMINATION; MULTIVARIATE ANALYSIS OF COVARIANCE; NEUROPSYCHIATRY; PRIORITY JOURNAL; SCORING SYSTEM; SLEEP PATTERN; AGED; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; MALE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALANTAMINE; HUMANS; MALE; PREVALENCE; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS;

EID: 0642371921     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/26.5.602     Document Type: Article

References (30)

1. McCurry SM, Logsdon RG, Teri L, et al Characteristics of sleep disturbance in community-dwelling Alzheimer disease patients. J Geriatr Psychiatry Neurol 1999;12:53-9.
2. Moe KE, Vitiello MV, Larsen LH, Prinz PN Symposium, cognitive processes and sleep disturbances: sleep/wake patterns in Alzheimer's disease, relationships with cognition and function J Sleep Res 1995;4:15-20.
3. rd, Kupfer DJ, Taska LS, et al. EEG sleep in elderly depressed, demented, and healthy subjects. Biol Psychiatry 1985;20:431-42.
4. Chokroverty S Sleep disorders in elderly persons In Chokroverty S, ed. Sleep disorders medicine basic science, technical considerations, and clinical aspects. Boston: Butterworth-Heinemann, 1994;401-15.
5. Christos GA. Is Alzheimer's disease related to a deficit or malfunction of rapid eye movement (REM) Sleep? Med Hypotheses 1993;41:435-9.
6. Burns A, Rossor M, Hecker J, et al The effects of donepezil in Alzheimer's disease-results from a multinational trial Dement Geriatr Cogn Disord 1999;10:237-44.
7. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
8. Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USA-1 Study Group. Galantamine in AD a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8.
9. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-31.
10. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology 1998;50:136-45.
11. Rosler M, Anand R, Cicin-Sain A, et al Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial BMJ 1999;318:633-40.
12. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76.
13. Wilcock GK, Lilienfeld S, Gaens E, Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000;321:1445-9.
14. Blesa R. Galantamine. Therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000;11(supp 11):28-34.
15. th Congress of the International Psychogenatric Association (IPA). Nice, France, September 9-17, 2001.
16. Fillit H, Gutterman, EM, Brooks, RL. The impact of donepezil on caregiving burden for patients with Alzheimer's disease Int Psychogeriatr 2000;12:389-401.
17. Shikiar R, Shakespeare A, Sagnier P, et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial J Am Geriatr Soc 2000;48:268-274.
18. th Congress of the International Psychogeriatric Association (IPA). Nice, France, September 9-17, 2001.
19. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR. Acta Neurol Scand 2000;176(Suppl):68-73.
20. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D, Galantamine International-2 Study Group. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
21. Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
22. Cummings JL The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(Suppl 6):S10-6.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Neurology 1994;44:2308-14.
24. Kaufer DI, Cummings JL, Christine D Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
25. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds Am J Psychiatry 2000;157:4-15.
26. de Jesus Cabeza R, Zoltoski RK, Gillin JC. Biochemical pharmacology of sleep. In: Chokroverty S, ed. Sleep disorders medicine: basic science, technical considerations, and clinical aspects. Boston: Butterworth-Heinemann; 1994:37-56.
27. Gilman PK Tacrine for treatment of sleep disturbance in dementia J Am Geriatr Soc 1997;45:1286.
28. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000;55:870-871.
29. Ross JS, Shua-Haim JR. Aricept-induced nightmares in Alzheimer's disease: 2 case reports. J Am Geriatr Soc 1998;46:119-20.
30. th Annual Meeting of the American Association of Geriatric Psychiatry, February 23-26, 2001, San Francisco, CA.